Section Arrow
ELVN.NASDAQ
- Enliven Therapeutics
Quotes are at least 15-min delayed:2026/06/02 18:46 EDT
After Hours
Last
 35.49
-0.03 (-0.08%)
Bid
34.89
Ask
35.5
High 35.86 
Low 34.89 
Volume 16.77K 
Regular Hours (Closed)
Last
 35.52
-1.99 (-5.31%)
Day High 
37.53 
Prev. Close
37.51 
1-M High
45.1399 
Volume 
1.81M 
Bid
34.89
Ask
35.5
Day Low
35.42 
Open
37.3 
1-M Low
36.85 
Market Cap 
2.28B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 40.71 
20-SMA 41.12 
50-SMA 41.19 
52-W High 48.53 
52-W Low 14.785 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.64/-1.77
Enterprise Value
2.28B
Balance Sheet
Book Value Per Share
7.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1098-0.0032-2.83%-- 
After Hours 0.1087 -0.0011 -1.00%
FULCFulcrum Therapeutics3.14-3.28-51.09%-- 
After Hours 3.1199 -0.0201 -0.64%
AIMAIM ImmunoTech Inc.0.8267-0.0719-8.00%-- 
After Hours 0.751 -0.0757 -9.16%
EVGNEvogene Ltd.0.5901-0.0929-13.60%-- 
After Hours 0.6214 +0.0313 +5.30%
HRTXHeron Therapeutics0.45-0.3772-45.60%-- 
After Hours 0.467 +0.017 +3.78%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.